ing amyloid protein deposition in atrial tissues in aged hearts, dysregulation of the unfolded protein response may lead to peptide aggregates that activate NLRP3 and promote mitochondrial dysfunction. 8 AF susceptibility was also associated with downregulation of genes associated with oxidoreductase activity and upregulation of decarboxylase, aldolase, cyclase, and electron transport activity, 7 supporting a role for metabolic stress and mitochondrial dysfunction in AF that may trigger NLRP3 inflammasome activation.
In an elegant set of experiments, Yao et al 2 used a robust mixture of human tissue studies, an in vivo canine atrial tachycardia pacing model, and several carefully chosen genetically modified mouse models. They report that, although NLRP3 levels in human right atrial tissue were unchanged in patients with paroxysmal AF versus controls, caspase-1 was activated, consistent with increased NLRP3 activity. In contrast, for patients with persistent AF, levels of NLRP3, ASC, and active caspase-1 (Casp1-p20) were all elevated. The canine atrial tachypacing model resembled patients with paroxysmal AF; no change in NLRP3 abundance was evident, but activated caspase-1 was elevated. By 2 months of age, CREM-TG mice (one of a few models of spontaneous AF) showed increased atrial expression of NLRP3, ASC, active caspase-1, and increased atrial ectopy, before the onset of spontaneous AF. Atrial ectopy precedes and predicts AF in humans as well. 9 Because the NLRP3 inflammasome also plays a significant role in innate immune cells, Yao et al 2 evaluated macrophage infiltration (CD68) in each of their systems. CD68 protein levels were unchanged in human paroxysmal AF atria and in the canine atrial tachypacing model, but increased in human persistent AF, suggesting that, although macrophages are not critical at the onset of AF, they may promote AF progression and persistence. NLRP3 protein was detectable in human, canine, and mouse atrial myocytes. The authors developed a line of mice that expressed a cardiomyocyte-specific NLRP3 gain-of-function knock-in (CM-KI). Like patients with paroxysmal AF, these mice had more frequent atrial ectopy and reproducible pacing-induced AF. Endoplasmic reticulum stress associated with obesity, hypoxia, and ischemia also activates NLRP3 receptors, resulting in increased IL-1β and IL-18 production. Protein and peptide aggregates elicit the unfolded protein response; this promotes autophagy and mitophagy, resulting in impaired mitochondrial function and reactive oxygen species (ROS) production that increases spontaneous release of calcium from the sarcoplasmic reticulum, contributing to atrial ectopy that can initiate episodes of atrial fibrillation. ASC indicates Apoptosis-associated Speck-like Protein Containing a Caspase Recruitment Domain; IL, interleukin; IP3, inositol triphosphate; and NF-κB, nuclear factor κB. Using the CM-KI model, the authors established causal links between NLRP3 inflammasome activation and atrial arrhythmias by demonstrating that: (1) a selective inflammasome inhibitor (MCC950) that interrupts NLRP3 inflammasome complex assembly prevented AF inducibility and (2) cardiomyocyte-specific knockdown of NLRP3 reduced AF inducibility and restored normal mRNA levels of Ryr2, Kcna5, Girk1, and Girk4. Their studies also implicate NLRP3 inflammasome activation as a contributor to electric and structural remodeling. NLRP3 activity may contribute to abbreviation of the atrial effective refractory period that is often observed in patients with AF and experimental models, and to atrial hypertrophy and fibrosis that promote AF persistence. Caution is warranted in extrapolating from the electrophysiological changes observed in mice, given their shorter refractory period and greater density of repolarizing K + currents. Nevertheless, these studies suggest that targeting NLRP3 inflammasome activation may have therapeutic benefit.
Because inflammasome activation leads to IL-1β activation, 5 a potential therapeutic candidate in this setting is canakinumab, a monoclonal antibody that blocks interaction of activated IL-1β with its receptors ( Figure) , and the drug tested in the CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study). 10 In patients with a prior myocardial infarction and elevated CRP, canakinumab lowered plasma CRP levels and reduced cardiovascular events.
11 Event reduction paralleled changes in CRP level. 12 Because AF was a prespecified end point in the CANTOS trial, we await results from this substudy with interest.
A recent study also showed that the NLRP3 inflammasome is a key signaling element in the systemic inflammatory response to a Western diet. 13 Obesity is an important risk factor for AF, 14 and weight loss is associated with a reduction in CRP levels. 15 Thus, in addition to pharmacological targeting of NLRP3, dietary/lifestyle changes may also help to reduce the burden of obesity and the NLRP3-associated inflammatory pathophysiology that promotes atrial ectopy and creates an AF substrate that increases its persistence.
In summary, the study by Yao et al 2 provides novel and important insights into the significance and potentially causative role of NLRP3 inflammasome activation as a mediator of inflammatory signaling in atrial pathophysiology and as a candidate target for therapeutic intervention. This study used both gain-of-function studies to demonstrate the sufficiency of NLRP3 in the initiation of AF, and loss-of-function studies to document the critical role of this pathway in AF initiation and progression. It also points the way toward more specific targeting of the inflammasome pathways for therapeutic intervention. It is hopeful that this specificity will yield more successful upstream therapies for AF than earlier efforts that used nonspecific anti-inflammatory agents. In summary, this study represents a significant advance. Further work in this intriguing area seems likely to be fruitful. 
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